The frequency of neurological and psychiatric complaints for participants taking rilpivirine,
elvitegravir, or dolutegravir reaches on average 20—30% during clinical trials. The inclusion
and exclusion criteria for enrolling people living with HIV are at times so selective and the
subsequent descriptions of minor or severe adverse events (AE's) so often imprecise and
ambiguous that one cannot extrapolate these particular research results to practicing
medicine. These adverse events negatively affect the patient's quality of life and ultimately
his or her good adherence to treatments.
This study aims at assessing the prevalence and at describing the neurological and
psychiatric adverse events related to these drugs.